**HMG-CoA Reductase Inhibitors and HMG-CoA Reductase Inhibitor Combination Drugs**

**Policy #** 00339  
**Original Effective Date:** 01/09/2013  
**Current Effective Date:** 10/18/2017

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

**When Services May Be Eligible for Coverage**  
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

**For Patients With “Step Therapy” (generic before brand) ONLY:**  
Based on review of the available data, brand name HMG-CoA reductase inhibitors (statins) and brand name HMG-CoA reductase inhibitor combination drugs, including, but not limited to Lipitor® (atorvastatin), Livalo® (pitavastatin), Vytorin® (simvastatin/ezetimibe), Caduet® (atorvastatin/amlodipine), and Altoprev® (lovastatin) may be considered to be eligible for coverage when one of the below patient selection criteria are met:

**Patient Selection Criteria:**
Coverage eligibility will be considered for brand name HMG-CoA reductase inhibitors and brand name HMG-CoA reductase inhibitor combination drugs when one of the following criteria is met:

- The patient has tried and failed one generic HMG-CoA reductase inhibitor (e.g., atorvastatin, lovastatin, pravastatin, fluvastatin, simvastatin, rosuvastatin); or
- There is clinical evidence or patient history that suggests the generically available products will be ineffective or cause an adverse reaction to the patient.

**When Services Are Considered Not Medically Necessary**  
Based on review of available data, the Company considers the use of brand name HMG-CoA reductase inhibitors and brand name HMG-CoA reductase inhibitor combination drugs when patient selection criteria are not met to be **not medically necessary.**

**For Patients With “Prior Authorization” ONLY:**  
Based on review of the available data, the Company may consider Livalo (pitavastatin), Altoprev (lovastatin), and Crestor® (rosuvastatin) to be eligible for coverage when the below patient selection criteria are met for the requested drug:

**Patient Selection Criteria**
Coverage eligibility will be considered for Livalo (pitavastatin), Altoprev (lovastatin), or Crestor (rosuvastatin) when the following criteria are met for the requested drug:

- For Crestor requests: Patient has tried and failed at least TWO generic HMG-CoA reductase inhibitor products (one of which MUST be generic rosuvastatin) unless there is clinical evidence or...
patient history that suggests the use of TWO generic HMG-CoA reductase inhibitor products will be ineffective or cause an adverse reaction to the patient.

- For Altoprev or Livalo requests: Patient has tried and failed at least TWO generic HMG-CoA reductase inhibitor products (e.g. atorvastatin, lovastatin, pravastatin, fluvastatin, simvastatin, rosuvastatin) unless there is clinical evidence or patient history that suggests the use of TWO generic HMG-CoA reductase inhibitor products will be ineffective or cause an adverse reaction to the patient.

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of Livalo (pitavastatin), Altoprev (lovastatin), or Crestor (rosuvastatin) when the patient selection criteria for the requested drug are not met to be not medically necessary.**

For Patients With BOTH “Prior Authorization” AND “Step Therapy”:
Based on review of the available data, brand name HMG-CoA reductase inhibitors (statins) and brand name HMG-CoA reductase inhibitor combination drugs, including, but not limited to Lipitor (atorvastatin), Livalo (pitavastatin), Vytorin (simvastatin/ezetimibe), Caduet (atorvastatin/amlodipine), and Altoprev (lovastatin) may be considered to be eligible for coverage when the below patient selection criteria are met for the requested drug:

Patient Selection Criteria
Coverage eligibility will be considered for brand name HMG-CoA reductase inhibitors and brand name HMG-CoA reductase inhibitor combination drugs when the following criteria are met for the requested drug:

- For Altoprev or Livalo requests: Patient has tried and failed at least TWO generic HMG-CoA reductase inhibitor products (e.g., atorvastatin, lovastatin, pravastatin, fluvastatin, simvastatin, rosuvastatin) unless there is clinical evidence or patient history that suggests the use of TWO generic HMG-CoA reductase inhibitor products will be ineffective or cause an adverse reaction to the patient.

- For Crestor requests: Patient has tried and failed at least TWO generic HMG-CoA reductase inhibitor products (one of which MUST be generic rosuvastatin) unless there is clinical evidence or patient history that suggests the use of TWO generic HMG-CoA reductase inhibitor products will be ineffective or cause an adverse reaction to the patient.

- For ALL other requests: The patient has tried and failed one generic HMG-CoA reductase inhibitor (e.g. atorvastatin, lovastatin, pravastatin, fluvastatin, simvastatin, rosuvastatin) unless there is clinical evidence or patient history that suggests the generically available products will be ineffective or cause an adverse reaction to the patient.

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of brand name HMG-CoA reductase inhibitors and brand name HMG-CoA reductase inhibitor combination drugs when patient selection criteria are not met to be not medically necessary.**

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
HMG-CoA Reductase Inhibitors and HMG-CoA Reductase Inhibitor Combination Drugs

Policy # 00339
Original Effective Date: 01/09/2013
Current Effective Date: 10/18/2017

Background/Overview
HMG Co-A reductase inhibitors (statins) and statin combination drugs are used to treat lipid abnormalities. There are various products in this class that have a generic equivalent. The two products that don’t have a generic equivalent are Livalo and Altoprev. There are alternative generic statins available that produce similar cholesterol lowering effects as Livalo and Altoprev. There are also generic alternatives available for CYP 3A4 drug interaction concerns (e.g., pravastatin). Crestor does have a generic equivalent that was recently launched, but the branded product is more expensive and continues to carry a significant portion of the market share in the class, therefore a shift to generic utilization of this product is necessary.

Rationale/Source
The patient selection criteria presented in this policy takes into consideration clinical evidence or patient history that suggests the generically available products will be ineffective or cause an adverse reaction to the patient. Based on a review of the data, in the absence of the above mentioned caveat, there is no advantage of using a brand name HMG Co-A reductase inhibitor (statin) or brand name statin combination drug over the available generic statins or generic statin combination drugs. Generic drugs are considered to have equal bioavailability and efficacy in comparison to brand name drugs. In the instance where there is not a generic equivalent, there are generic alternatives available that produce similar clinical outcomes in this drug class.

References
1. Express Scripts Statin Step Therapy Policy. 11/2012.

Policy History
Original Effective Date: 01/09/2013
Current Effective Date: 10/18/2017
01/03/2013 Medical Policy Committee review
01/09/2013 Medical Policy Implementation Committee approval. New policy.
02/19/2013 Format revision. Coding section removed.
11/07/2013 Medical Policy Committee review
11/20/2013 Medical Policy Implementation Committee approval. Removed Crestor from step therapy program.
11/06/2014 Medical Policy Committee review
10/29/2015 Medical Policy Committee review
11/16/2015 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/06/2016 Medical Policy Committee review
10/19/2016 Medical Policy Implementation Committee approval. Added prior authorization to Livalo, Altoprev, and Crestor. Split into PA, step, and step/PA.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
HMG-CoA Reductase Inhibitors and HMG-CoA Reductase Inhibitor Combination Drugs

Policy # 00339
Original Effective Date: 01/09/2013
Current Effective Date: 10/18/2017

10/05/2017 Medical Policy Committee review
10/18/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
Next Scheduled Review Date: 10/2018

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.